A commentary in ChemBioChem by UC Santa Cruz professor Jevgenij Raskatov argues that P3, a peptide long dismissed as harmless, may play a part in Alzheimer's disease. P3 forms when the Amyloid Precursor Protein is cut in a different sequence than the one that produces amyloid beta. For years, scientists largely assumed P3 could not form deposits, was not toxic to cells, and would simply dissolve in water, so it received little research attention.
Raskatov's laboratory tested those assumptions. Across three major studies published over the past five years, the team reported that P3 can form amyloid deposits at least as readily as amyloid beta, and in their experiments it produced these aggregates more quickly. They also found evidence that P3 may be harmful to neurons, though its toxicity appears lower than that of amyloid beta. According to Raskatov, an independent group in the United Kingdom has confirmed and extended some of these findings, and other laboratories are starting to study how P3 and amyloid beta interact.
The work matters because amyloid beta has dominated Alzheimer's research for decades, and more than 400 clinical trials have targeted it, with many failing or producing only modest benefits. Existing treatments, including the recently approved antibody drugs Lecanemab and Donanemab, have limits, and Raskatov argues that the field needs fundamentally new approaches. If P3 contributes to nerve cell damage, it could point to targets that current therapies do not address.
The researchers are clear that the findings do not yet establish how much P3 contributes to the disease in patients. David Teplow, an emeritus professor of neurology at UCLA, reviewed Raskatov's research and said it has far-reaching consequences for basic science and clinical research. Raskatov also flagged at least four peer-reviewed papers that cited his lab's work as evidence that P3 was harmless, the opposite of what his team reported, and he said it remains unclear how that misreading occurred.